<DOC>
	<DOCNO>NCT00688207</DOCNO>
	<brief_summary>The present pharmacokinetic study design ass pharmacokinetics RSG XR monotherapy patient mild Alzheimer 's disease ( AD ) information obtain current phase III trial . The study aim enroll fourteen patient ( seven APOE genotype ) . Each patient receive single oral dose 4mg RSG XR morning fast condition PK sample take 36h .</brief_summary>
	<brief_title>Mild Alzheimer '' Disease Assess Extended Release Formulation Rosiglitazone ( RSG XR )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Male female subject clinical diagnosis probable Alzheimer 's disease accordance NINCDSADRDA3 criterion least 3 month Subject mild Alzheimer 's disease define MMSE score 18 26 inclusive Screening Hachinski Ischemia Score ≤ 4 Screening Subjects age ≥50 ≤90 year . Subject take approve Alzheimer 's therapy last 30 day . Current use medication accordance criterion list Section 9.1 ) . Female subject must postmenopausal ( i.e . &gt; 1 year without menstrual period ) , surgically sterile , agree use adequate method contraception duration study . Female subject premenopausal postmenopausal &lt; 1 year must undertake pregnancy test screening , must negative . More one pregnancy test may require ( i.e. , time period enrolment study treatment &gt; 7 day ) . Pregnancy test perform screening , predose ( Day 1 ) followup visit woman childbearing potential postmenopausal less 1 year . If clinically indicate , urine serum pregnancy test may perform anytime study . Brain CT MRI scan perform within past 12 month Screening , show evidence potential cause dementia Alzheimer 's disease . Neurological exam without focal change ( exclude change attributable AD peripheral trauma ) . Subjects live regular caregiver willing attend visit , oversee subject 's compliance protocol specify procedure study medication , willing report subject 's status . Subject provide full write informed consent prior performance protocolspecified procedure . Subjects consider enrolment must QTc ( either QTc B ( Bazett 's correction ) QTc F ( Fridericia 's correction ) ) &lt; 450msec Screening Visit , exception subject bundle branch block ( either QTc B QTc F must &lt; 480msec ) . Diagnosis possible , probable , definite vascular dementia accordance NINDSAIREN6 criterion History evidence CNS disorder could interpret cause dementia : e.g . cerebrovascular disease ( stroke , hemorrhage ) , structural abnormality , epilepsy , infectious inflammatory/demyelinating CNS condition , Parkinson 's disease . Evidence follow disorder : current vitamin B12 deficiency , positive syphilis serology active thyroid dysfunction ( particularly suggestive hypothyroidism ) , include abnormally high low serum level thyroid stimulate hormone ( TSH ) clinically significant opinion investigator . History Type 1 diabetes mellitus secondary diabetes mellitus . Type 2 diabetes mellitus subject treated insulin , PPARγ agonist , insulin secretagogue ( e.g . sulfonylurea glitinide ) . Any patient HbA1c ≥8.5 % History clinical/laboratory evidence congestive heart failure define New York Heart Association criterion ( Class I IV cardiac status ) ( Appendix 4 ) . History cardiovascular event within last 6 month ( i.e . intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ] significant arrhythmia ; major intervention ( e.g . cardiac surgery angiography plus stenting ) schedule ) . History significant psychiatric illness schizophrenia bipolar affective disorder opinion Investigator would interfere participation study , major depressive disorder ( accord DSMIV ) past year , current active depression require initiation treatment . History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug , clinically relevant abnormality , , opinion Investigator , make subject unsuitable inclusion study . Clinically significant peripheral oedema time screen . Current recent drug alcohol abuse dependence ( define DSMIV criterion substancerelated disorder ) , recent remote history could contribute factor dementia . Systolic blood pressure &gt; 165 &lt; 90 mmHg diastolic blood pressure &gt; 95 &lt; 60 mmHg time screen . Clinically significant anaemia ( i.e . haemoglobin &lt; 11 g/dL male &lt; 10 g/dL female ) Patients GFR ≤50ml/min ( assess CockcroftGault method ) . ALT , AST , alkaline phosphatase value &gt; 2.5 time upper limit normal , total bilirubin value &gt; 1.5 time upper limit normal , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis , ChildPugh Class B/C ) . History bone marrow transplant . Positive hepatitis B virus , hepatitis C virus HIV test screening . Subject unable ( assistance , appropriate ) take study medication risk noncompliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PPAR agonist ,</keyword>
	<keyword>Rosiglitazone XR ,</keyword>
	<keyword>BRL-049653 .</keyword>
	<keyword>Alzheimer 's disease ,</keyword>
</DOC>